

## STRATEGY DINNER

# AI with Purpose: Strategy-First Innovation Across Drug Discovery

As therapeutic pipelines grow in complexity, many organizations struggle to deploy AI/ML meaningfully across early R&D. Challenges include fragmented data ecosystems, siloed teams, and difficulty scaling models across modalities. This dinner roundtable brings together senior discovery and data leaders to explore how to implement AI strategies that scale, align with FAIR principles, and accelerate decision-making across small molecules, biologics, and new modalities. The discussion will highlight actionable strategies for unifying chemical and biological data, enhancing model reliability, and fostering cross-functional buy-in for digital transformation.

### TOPICS INCLUDE:

- ✓ AI & ML implementation in drug discovery workflows
- ✓ Data interoperability across therapeutic areas and modalities
- ✓ FAIR data practices to enable reusability and collaboration
- ✓ Platform strategies that bridge chemistry and biology

### AGENDA:

17:15 - 18:00	Registration, Networking & Cocktails
18:00 - 18:30	Welcome & Opening Remarks - <b>David Gosalvez, Revvity</b>
18:30 - 19:30	Roundtable: <b>Solving AI-Driven Discovery at Scale - From Concept to Clinical Candidate</b>
19:30 - 20:30	Dinner
20:30 - 21:30	Roundtable: <b>Designing FAIR-Centric Data Platforms for the Future of Multimodal R&amp;D</b>
21:30 - 22:00	Coffee, Cognac & Closing Remarks

### KEY OPINION LEADERS:



**Dr. David Gosalvez** — *Chief Strategy Officer, Revvity Signals Software*

Dr. Gosalvez brings 25 years of scientific software and analytics expertise, combining deep technical knowledge with broad scientific domain understanding. As head of Product Strategy, he shapes the Revvity Signals Informatics portfolio through direct collaboration with scientists and IT leaders across pharmaceutical and chemical industries.

His leadership spans:

- **Strategic Software Innovation** driving scientific efficiency and quality improvements
- **Cross-Industry Partnerships** integrating complementary capabilities and AI/ML models
- **Transformative Product Development** including ChemDraw, Spotfire Lead Discovery, and the Oracle Chemistry Cartridge

Previously served as Director of Cheminformatics, Executive Director of Application Development at CambridgeSoft, and led the Science & Technology team that created Revvity Signals platform's foundational data management technologies.



**Dr. Anastasia Christianson** — *Managing Principal, EPAM Life Science Consulting & Executive in Residence, Columbia Ventures*

Dr. Christianson, a Pharmaceutical AI & Data Science Pioneer, brings nearly three decades of pharmaceutical industry transformation as former SVP and Global Head of AI at Pfizer and leader at J&J, BMS, and AstraZeneca.

Her unparalleled expertise spans:

- **Strategic AI Implementation** that delivers measurable business value
- **Global AI Policy Leadership** through White House and National Academy of Medicine engagements
- **Cross-Industry Innovation** as advisor to biotech startups, venture capital, and global health initiatives

### ABOUT REVVITY SIGNALS:

**Revvity Signals Software** provides an extensive range of scientific solutions, empowering researchers and pharmaceutical pioneers worldwide. Our cutting-edge technology simplifies processes, speeds up experiments, and prioritizes promising compounds, redefining drug discovery. The Signals Research Suite, our flagship solution, streamlines R&D workflows with data capture, collaboration, data processing, and data-driven analytics. It includes i Signals Notebook, the only cloud-native electronic lab notebook with ChemDraw®, Spotfire® powered advanced analytics, as well as next-gen data management. In addition, we have recently introduced Signals Synergy which is designed to substantially enhance collaboration, project management, and data exchange between sponsors and CROs.